Skip to main content

Expecting another solid result

Technology One is scheduled to report its 1HFY22 result on Tuesday, 24th May and we anticipate a solid result with forecast low double digit revenue and PBT growth. In our view, however, the key highlight will be the level of SaaS ARR growth which we expect to be strong given the level of SaaS flips are likely to be accelerating. We forecast SaaS ARR growth of 38% to c.$215m and, furthermore, forecast total ARR growth of 18% to c.$275m. One offsetting impact, however, of the expected accelerating SaaS flips is the level of on premise initial licence fees is likely to fall materially – we forecast a 44% fall to $2.0m – and while this is a headwind for earnings we believe it is positive overall that these licence fees are rapidly diminishing. We also expect Technology One to provide FY22 guidance at the release of the interim result and expect the usual 10-15% growth in PBT with the likelihood this will be towards the upper end despite the rapid decline of on premise initial licence fees.

No change in forecasts

There is no change in our forecasts and we wait for the release of the 1HFY22 result before looking to reassess. We already forecast strong PBT growth of 16% in FY22 which is slightly above the top end of the 10-15% growth we expect the company to provide as FY22 guidance. The key swing factor this year is likely to be the level of on premise initial licence fees and if, for instance, Technology One is still able to generate a result towards the top end of the usual 10-15% growth range despite a material fall in these licence fees then this will further increase the quality of the result.

Investment view: PT down 11% to $12.50, Maintain BUY

While there is no change in our forecasts we have updated each valuation used in the determination of our price target for market movements and time creep. There are no changes in the key assumptions we apply which are a 15% discount in the relative valuations and an 8.5% WACC and 5.0% terminal growth rate in the DCF. The net result is an 11% decrease in our PT to $12.50 which has all been driven by a reduction in the relative valuations. We maintain our BUY recommendation.

To read the full report click the button below.

View Detailed Report
Authored by Chris Savage – Analyst – at Bell Potter Securities, 10 May 2022
Important Disclaimer—This may affect your legal rights: Because this document has been prepared without consideration of any specific client’s financial situation, particular needs and investment objectives, a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the proper authority of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be consulted before any investment decision is made. While this document is based on the information from sources which are considered reliable, Bell Potter Securities Limited, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility to inform you of any matter that subsequently comes to its notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. This is general investment advice only and does not constitute advice to any person.
Disclosure of Interest: Bell Potter Securities Limited receives commission from dealing in securities and its authorised representatives, or introducers of business, may directly share in this commission. Bell Potter Securities and its associates may hold shares in the companies recommended.